Interstitial lung diseases (ILDs) represent a diverse group of over 200 lung disorders characterized by inflammation and fibrosis of the alveolar walls. This article provides a comprehensive overview of the causes, symptoms, and treatment strategies for ILDs.
ILDs may be idiopathic or associated with various factors such as occupational and environmental exposures, systemic diseases, and certain medications. Smoking, age, and a family history of ILDs are other significant risk factors.
Patients with ILDs typically present with progressive dyspnea and non-productive cough. Other symptoms may include fatigue, weight loss, and clubbing. The physical examination may reveal inspiratory crackles and signs of pulmonary hypertension in advanced stages.
High-resolution computed tomography (HRCT) is the imaging modality of choice for ILDs, providing detailed images of the lung parenchyma. Pulmonary function tests reveal a restrictive pattern with reduced diffusing capacity for carbon monoxide. In certain cases, a lung biopsy may be necessary to establish a definitive diagnosis.
Management of ILDs involves addressing the underlying cause, if identified, and slowing disease progression. Pharmacologic therapy includes corticosteroids and immunosuppressive agents. Antifibrotic drugs such as pirfenidone and nintedanib have shown efficacy in idiopathic pulmonary fibrosis. Lung transplantation may be considered in selected patients with advanced disease.
Given the chronic and progressive nature of ILDs, palliative care focusing on symptom management and improving quality of life is essential. The prognosis varies widely depending on the specific type of ILD, ranging from relatively benign to rapidly progressive and fatal.
Interstitial lung diseases are complex disorders requiring a comprehensive approach to diagnosis and management. Understanding the diverse etiologies, recognizing the clinical manifestations, and being familiar with the current treatment strategies are crucial for optimal patient care.
1.
Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap
2.
Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal
3.
Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study
4.
The amount of liver tissue removed during gallbladder surgery has no discernible impact on overall survival.
5.
Long-Acting Interferon Therapy Approved for ET
1.
Molecular Network Mapping in Hematologic Disease
2.
Metabolic Reprogramming of the Tumor Microenvironment: Mechanisms, Clinical Relevance, and Emerging Therapeutic Strategies
3.
Hematopoietic Stem Cell Clonal Dynamics Across the Lifespan
4.
Connected Hematology Laboratory Networks for Automated Cross-Institution Data Exchange
5.
Digital Oncology Ecosystems Integrating Longitudinal Patient Trajectories: Transforming Cancer Care through Data-Driven Innovation
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
2.
Common side effects of cancer treatment and how they are managed
3.
Clinical Excellence in Hematology
4.
Best Practices in Hematology
5.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation